Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more and get updates at SpurTherapeutics.com.
This site will remain live until Q4 2024 as we transition content to our new site.
We are progressing our lead program in AMN (SBT101), in addition to further developing a pipeline of gene therapy candidates designed to be delivered intrathecally. Our forward momentum is currently powered by a $56M Series B investment from our long-term, committed investment partners.
Follow our progress and read our most recent announcements:
